Hyperfine, Inc. (NASDAQ: HYPR) Stock Competitors & Peer Comparison
See HYPR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HYPR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HYPR | $0.90 | -0.22% | 76M | -2.44 | -$0.37 | N/A |
| ABT | $116.64 | +2.19% | 201.8B | 22.39 | $5.21 | +2.13% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $329.45 | +0.53% | 126.3B | 24.59 | $13.39 | +1.06% |
| MDT | $93.35 | +1.14% | 119.5B | 16.88 | $5.53 | +3.06% |
| BSX | $50.37 | +2.03% | 74.9B | 16.25 | $3.10 | N/A |
| EW | $89.79 | -0.04% | 51.7B | 33.26 | $2.70 | N/A |
| DXCM | $92.34 | +2.35% | 34.8B | 36.21 | $2.55 | N/A |
| GEHC | $74.82 | +1.03% | 33.8B | 16.41 | $4.56 | +0.19% |
| RMD | $231.52 | +1.35% | 33.6B | 21.49 | $10.77 | +1.06% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
HYPR vs ABT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ABT has a market cap of 201.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ABT trades at $116.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ABT's P/E ratio is 22.39. In terms of profitability, HYPR's ROE is -1.00%, compared to ABT's ROE of +0.11%. Regarding short-term risk, HYPR is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
HYPR vs BSX-PA Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, HYPR's ROE is -1.00%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, HYPR is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
HYPR vs SYK Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SYK has a market cap of 126.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SYK trades at $329.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SYK's P/E ratio is 24.59. In terms of profitability, HYPR's ROE is -1.00%, compared to SYK's ROE of +0.16%. Regarding short-term risk, HYPR is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SYK's competition here
Medtronic plc (NYSE: MDT)
HYPR vs MDT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, MDT has a market cap of 119.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while MDT trades at $93.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas MDT's P/E ratio is 16.88. In terms of profitability, HYPR's ROE is -1.00%, compared to MDT's ROE of +0.10%. Regarding short-term risk, HYPR is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
HYPR vs BSX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BSX has a market cap of 74.9B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BSX trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BSX's P/E ratio is 16.25. In terms of profitability, HYPR's ROE is -1.00%, compared to BSX's ROE of +0.15%. Regarding short-term risk, HYPR is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
HYPR vs EW Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while EW trades at $89.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas EW's P/E ratio is 33.26. In terms of profitability, HYPR's ROE is -1.00%, compared to EW's ROE of +0.10%. Regarding short-term risk, HYPR is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
HYPR vs DXCM Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, DXCM has a market cap of 34.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while DXCM trades at $92.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas DXCM's P/E ratio is 36.21. In terms of profitability, HYPR's ROE is -1.00%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, HYPR is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
HYPR vs GEHC Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, GEHC has a market cap of 33.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while GEHC trades at $74.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas GEHC's P/E ratio is 16.41. In terms of profitability, HYPR's ROE is -1.00%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HYPR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check GEHC's competition here
ResMed Inc. (NYSE: RMD)
HYPR vs RMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, RMD has a market cap of 33.6B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while RMD trades at $231.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas RMD's P/E ratio is 21.49. In terms of profitability, HYPR's ROE is -1.00%, compared to RMD's ROE of +0.24%. Regarding short-term risk, HYPR is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
HYPR vs PHG Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PHG trades at $27.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PHG's P/E ratio is 15.67. In terms of profitability, HYPR's ROE is -1.00%, compared to PHG's ROE of +0.10%. Regarding short-term risk, HYPR is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
HYPR vs ZBH Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ZBH has a market cap of 19.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ZBH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ZBH's P/E ratio is 11.91. In terms of profitability, HYPR's ROE is -1.00%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, HYPR is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
HYPR vs ABMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ABMD's P/E ratio is 65.36. In terms of profitability, HYPR's ROE is -1.00%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, HYPR is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
HYPR vs PEN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PEN trades at $325.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PEN's P/E ratio is 84.91. In terms of profitability, HYPR's ROE is -1.00%, compared to PEN's ROE of +0.11%. Regarding short-term risk, HYPR is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
HYPR vs SWAV Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SWAV's P/E ratio is 78.76. In terms of profitability, HYPR's ROE is -1.00%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, HYPR is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
HYPR vs SNN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SNN has a market cap of 12.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SNN trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SNN's P/E ratio is 13.77. In terms of profitability, HYPR's ROE is -1.00%, compared to SNN's ROE of +0.12%. Regarding short-term risk, HYPR is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
HYPR vs GMED Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, GMED has a market cap of 11.7B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while GMED trades at $86.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas GMED's P/E ratio is 19.58. In terms of profitability, HYPR's ROE is -1.00%, compared to GMED's ROE of +0.12%. Regarding short-term risk, HYPR is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check GMED's competition here
Align Technology, Inc. (NASDAQ: ALGN)
HYPR vs ALGN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ALGN trades at $162.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ALGN's P/E ratio is 14.82. In terms of profitability, HYPR's ROE is -1.00%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, HYPR is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
HYPR vs GKOS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, GKOS has a market cap of 10.9B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while GKOS trades at $184.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas GKOS's P/E ratio is -214.86. In terms of profitability, HYPR's ROE is -1.00%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, HYPR is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
HYPR vs PODD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PODD trades at $148.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PODD's P/E ratio is 25.24. In terms of profitability, HYPR's ROE is -1.00%, compared to PODD's ROE of +0.27%. Regarding short-term risk, HYPR is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
HYPR vs BIO Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BIO trades at $380.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BIO's P/E ratio is 40.94. In terms of profitability, HYPR's ROE is -1.00%, compared to BIO's ROE of +0.03%. Regarding short-term risk, HYPR is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
HYPR vs BIO-B Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BIO-B trades at $365.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, HYPR's ROE is -1.00%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, HYPR is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
HYPR vs MASI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas MASI's P/E ratio is 44.43. In terms of profitability, HYPR's ROE is -1.00%, compared to MASI's ROE of +0.09%. Regarding short-term risk, HYPR is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
HYPR vs BRKR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BRKR trades at $59.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BRKR's P/E ratio is 29.93. In terms of profitability, HYPR's ROE is -1.00%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, HYPR is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
HYPR vs BRKRP Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BRKRP trades at $439.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BRKRP's P/E ratio is 238.80. In terms of profitability, HYPR's ROE is -1.00%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, HYPR is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
HYPR vs HAE Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while HAE trades at $108.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas HAE's P/E ratio is 21.71. In terms of profitability, HYPR's ROE is -1.00%, compared to HAE's ROE of +0.11%. Regarding short-term risk, HYPR is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
HYPR vs NARI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas NARI's P/E ratio is -59.24. In terms of profitability, HYPR's ROE is -1.00%, compared to NARI's ROE of -0.00%. Regarding short-term risk, HYPR is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
HYPR vs LIVN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while LIVN trades at $78.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas LIVN's P/E ratio is 18.70. In terms of profitability, HYPR's ROE is -1.00%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, HYPR is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
HYPR vs ITGR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ITGR trades at $125.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ITGR's P/E ratio is 19.71. In terms of profitability, HYPR's ROE is -1.00%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, HYPR is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
HYPR vs IRTC Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while IRTC trades at $128.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas IRTC's P/E ratio is -200.81. In terms of profitability, HYPR's ROE is -1.00%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, HYPR is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
HYPR vs AXNX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AXNX's P/E ratio is -709.80. In terms of profitability, HYPR's ROE is -1.00%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, HYPR is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
HYPR vs TMDX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, TMDX has a market cap of 3.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while TMDX trades at $94.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas TMDX's P/E ratio is 48.06. In terms of profitability, HYPR's ROE is -1.00%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, HYPR is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
HYPR vs AXGN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AXGN has a market cap of 2.7B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AXGN trades at $50.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AXGN's P/E ratio is 132.63. In terms of profitability, HYPR's ROE is -1.00%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, HYPR is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
HYPR vs BFLY Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BFLY trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BFLY's P/E ratio is -39.79. In terms of profitability, HYPR's ROE is -1.00%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, HYPR is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
HYPR vs UFPT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while UFPT trades at $309.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas UFPT's P/E ratio is 31.58. In terms of profitability, HYPR's ROE is -1.00%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, HYPR is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
HYPR vs ESTA Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ESTA trades at $72.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ESTA's P/E ratio is -57.67. In terms of profitability, HYPR's ROE is -1.00%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, HYPR is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
HYPR vs NUVA Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas NUVA's P/E ratio is 75.00. In terms of profitability, HYPR's ROE is -1.00%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, HYPR is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
HYPR vs NVCR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while NVCR trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas NVCR's P/E ratio is -11.18. In terms of profitability, HYPR's ROE is -1.00%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, HYPR is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
HYPR vs INSP Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while INSP trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas INSP's P/E ratio is 27.51. In terms of profitability, HYPR's ROE is -1.00%, compared to INSP's ROE of +0.18%. Regarding short-term risk, HYPR is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
HYPR vs CNMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CNMD trades at $51.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CNMD's P/E ratio is 11.29. In terms of profitability, HYPR's ROE is -1.00%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, HYPR is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check CNMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
HYPR vs TNDM Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while TNDM trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas TNDM's P/E ratio is -24.00. In terms of profitability, HYPR's ROE is -1.00%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, HYPR is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
HYPR vs ENOV Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ENOV trades at $26.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ENOV's P/E ratio is 7.46. In terms of profitability, HYPR's ROE is -1.00%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, HYPR is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ENOV's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
HYPR vs ATEC Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ATEC trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ATEC's P/E ratio is -158.00. In terms of profitability, HYPR's ROE is -1.00%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, HYPR is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ATEC's competition here
Artivion, Inc. (NYSE: AORT)
HYPR vs AORT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AORT trades at $28.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AORT's P/E ratio is 46.82. In terms of profitability, HYPR's ROE is -1.00%, compared to AORT's ROE of -0.01%. Regarding short-term risk, HYPR is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
HYPR vs HSKA Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas HSKA's P/E ratio is -62.49. In terms of profitability, HYPR's ROE is -1.00%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, HYPR is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
HYPR vs IART Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while IART trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas IART's P/E ratio is 7.09. In terms of profitability, HYPR's ROE is -1.00%, compared to IART's ROE of -0.01%. Regarding short-term risk, HYPR is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
HYPR vs PRCT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PRCT trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PRCT's P/E ratio is -11.18. In terms of profitability, HYPR's ROE is -1.00%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, HYPR is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
HYPR vs LMRI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while LMRI trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas LMRI's P/E ratio is -24.16. In terms of profitability, HYPR's ROE is -1.00%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, HYPR is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check LMRI's competition here
Avanos Medical, Inc. (NYSE: AVNS)
HYPR vs AVNS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AVNS's P/E ratio is 27.77. In terms of profitability, HYPR's ROE is -1.00%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, HYPR is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
HYPR vs IRMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while IRMD trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas IRMD's P/E ratio is 44.15. In terms of profitability, HYPR's ROE is -1.00%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, HYPR is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
HYPR vs SILK Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SILK's P/E ratio is -18.96. In terms of profitability, HYPR's ROE is -1.00%, compared to SILK's ROE of -0.35%. Regarding short-term risk, HYPR is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
HYPR vs FNA Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas FNA's P/E ratio is -19.83. In terms of profitability, HYPR's ROE is -1.00%, compared to FNA's ROE of -0.35%. Regarding short-term risk, HYPR is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
HYPR vs BVS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BVS has a market cap of 974.2M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BVS trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BVS's P/E ratio is 18.92. In terms of profitability, HYPR's ROE is -1.00%, compared to BVS's ROE of +0.28%. Regarding short-term risk, HYPR is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
HYPR vs CBLL Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CBLL has a market cap of 922.4M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CBLL trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CBLL's P/E ratio is -14.91. In terms of profitability, HYPR's ROE is -1.00%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, HYPR is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check CBLL's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
HYPR vs SIBN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SIBN has a market cap of 885.2M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SIBN trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SIBN's P/E ratio is -58.71. In terms of profitability, HYPR's ROE is -1.00%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, HYPR is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
HYPR vs AVR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AVR has a market cap of 873.1M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AVR trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AVR's P/E ratio is -4.03. In terms of profitability, HYPR's ROE is -1.00%, compared to AVR's ROE of -0.78%. Regarding short-term risk, HYPR is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check AVR's competition here
InMode Ltd. (NASDAQ: INMD)
HYPR vs INMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, INMD has a market cap of 865.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while INMD trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas INMD's P/E ratio is 10.46. In terms of profitability, HYPR's ROE is -1.00%, compared to INMD's ROE of +0.12%. Regarding short-term risk, HYPR is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check INMD's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
HYPR vs BBNX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BBNX has a market cap of 857.1M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BBNX trades at $19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BBNX's P/E ratio is -12.62. In terms of profitability, HYPR's ROE is -1.00%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, HYPR is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
HYPR vs CSII Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CSII's P/E ratio is -20.83. In terms of profitability, HYPR's ROE is -1.00%, compared to CSII's ROE of -0.14%. Regarding short-term risk, HYPR is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
HYPR vs VREX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas VREX's P/E ratio is 19.48. In terms of profitability, HYPR's ROE is -1.00%, compared to VREX's ROE of +0.05%. Regarding short-term risk, HYPR is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
HYPR vs AHCO Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, AHCO has a market cap of 766M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while AHCO trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas AHCO's P/E ratio is 11.49. In terms of profitability, HYPR's ROE is -1.00%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, HYPR is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
HYPR vs SSII Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SSII has a market cap of 717.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SSII trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SSII's P/E ratio is -69.92. In terms of profitability, HYPR's ROE is -1.00%, compared to SSII's ROE of -0.27%. Regarding short-term risk, HYPR is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check SSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
HYPR vs KIDS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, KIDS has a market cap of 658.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while KIDS trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas KIDS's P/E ratio is -21.74. In terms of profitability, HYPR's ROE is -1.00%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, HYPR is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
HYPR vs SRDX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SRDX's P/E ratio is -34.66. In terms of profitability, HYPR's ROE is -1.00%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, HYPR is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
HYPR vs CTKB Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CTKB trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CTKB's P/E ratio is -24.69. In terms of profitability, HYPR's ROE is -1.00%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, HYPR is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
HYPR vs DCTH Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, DCTH has a market cap of 591.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while DCTH trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas DCTH's P/E ratio is 1714.00. In terms of profitability, HYPR's ROE is -1.00%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, HYPR is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
HYPR vs APEN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas APEN's P/E ratio is -9.43. In terms of profitability, HYPR's ROE is -1.00%, compared to APEN's ROE of -0.85%. Regarding short-term risk, HYPR is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
HYPR vs CERS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CERS has a market cap of 562.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CERS trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CERS's P/E ratio is -55.69. In terms of profitability, HYPR's ROE is -1.00%, compared to CERS's ROE of -0.10%. Regarding short-term risk, HYPR is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
HYPR vs TCMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, TCMD has a market cap of 537.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while TCMD trades at $23.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas TCMD's P/E ratio is 22.06. In terms of profitability, HYPR's ROE is -1.00%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, HYPR is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check TCMD's competition here
ZimVie Inc. (NASDAQ: ZIMV)
HYPR vs ZIMV Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, HYPR's ROE is -1.00%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, HYPR is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ZIMV's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
HYPR vs NPCE Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, NPCE has a market cap of 478.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while NPCE trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas NPCE's P/E ratio is -24.61. In terms of profitability, HYPR's ROE is -1.00%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, HYPR is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
HYPR vs CLPT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CLPT has a market cap of 455.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CLPT trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CLPT's P/E ratio is -12.87. In terms of profitability, HYPR's ROE is -1.00%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, HYPR is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
HYPR vs SGHT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SGHT has a market cap of 449.4M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SGHT trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SGHT's P/E ratio is -14.75. In terms of profitability, HYPR's ROE is -1.00%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, HYPR is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
HYPR vs CARL Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CARL has a market cap of 448.6M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CARL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CARL's P/E ratio is -11.54. In terms of profitability, HYPR's ROE is -1.00%, compared to CARL's ROE of -0.38%. Regarding short-term risk, HYPR is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
HYPR vs PACB Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PACB has a market cap of 427.1M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PACB's P/E ratio is -3.35. In terms of profitability, HYPR's ROE is -1.00%, compared to PACB's ROE of -49.62%. Regarding short-term risk, HYPR is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
HYPR vs SENS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SENS has a market cap of 405.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SENS trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SENS's P/E ratio is -4.35. In terms of profitability, HYPR's ROE is -1.00%, compared to SENS's ROE of -1.66%. Regarding short-term risk, HYPR is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
HYPR vs OFIX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, OFIX has a market cap of 404.6M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while OFIX trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas OFIX's P/E ratio is -13.08. In terms of profitability, HYPR's ROE is -1.00%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, HYPR is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
HYPR vs CATX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CATX has a market cap of 367.2M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CATX trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CATX's P/E ratio is -2.42. In terms of profitability, HYPR's ROE is -1.00%, compared to CATX's ROE of -0.42%. Regarding short-term risk, HYPR is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check CATX's competition here
Electromed, Inc. (AMEX: ELMD)
HYPR vs ELMD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ELMD has a market cap of 327.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ELMD trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ELMD's P/E ratio is 33.80. In terms of profitability, HYPR's ROE is -1.00%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, HYPR is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
HYPR vs TLSI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, TLSI has a market cap of 324.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while TLSI trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas TLSI's P/E ratio is -3.14. In terms of profitability, HYPR's ROE is -1.00%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, HYPR is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
HYPR vs SMLR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas SMLR's P/E ratio is 3.92. In terms of profitability, HYPR's ROE is -1.00%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, HYPR is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check SMLR's competition here
CapsoVision, Inc. (NASDAQ: CV)
HYPR vs CV Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, CV has a market cap of 300.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while CV trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas CV's P/E ratio is -2.41. In terms of profitability, HYPR's ROE is -1.00%, compared to CV's ROE of -1.78%. Regarding short-term risk, HYPR is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check CV's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
HYPR vs TMCI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, TMCI has a market cap of 281.5M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while TMCI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas TMCI's P/E ratio is -4.62. In terms of profitability, HYPR's ROE is -1.00%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, HYPR is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
HYPR vs RXST Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, RXST has a market cap of 258.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while RXST trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas RXST's P/E ratio is -5.53. In terms of profitability, HYPR's ROE is -1.00%, compared to RXST's ROE of -0.17%. Regarding short-term risk, HYPR is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
HYPR vs RCEL Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, RCEL has a market cap of 249.9M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while RCEL trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas RCEL's P/E ratio is -6.99. In terms of profitability, HYPR's ROE is -1.00%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, HYPR is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check RCEL's competition here
Profound Medical Corp. (NASDAQ: PROF)
HYPR vs PROF Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, PROF has a market cap of 246.7M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while PROF trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas PROF's P/E ratio is -6.93. In terms of profitability, HYPR's ROE is -1.00%, compared to PROF's ROE of -0.56%. Regarding short-term risk, HYPR is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
HYPR vs MGRM Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas MGRM's P/E ratio is -12.00. In terms of profitability, HYPR's ROE is -1.00%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, HYPR is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
HYPR vs NVRO Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas NVRO's P/E ratio is -1.91. In terms of profitability, HYPR's ROE is -1.00%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, HYPR is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
HYPR vs STIM Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, STIM has a market cap of 208.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while STIM trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas STIM's P/E ratio is -6.82. In terms of profitability, HYPR's ROE is -1.00%, compared to STIM's ROE of -1.51%. Regarding short-term risk, HYPR is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
HYPR vs BSGM Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas BSGM's P/E ratio is -5.81. In terms of profitability, HYPR's ROE is -1.00%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, HYPR is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
HYPR vs LUCD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, LUCD has a market cap of 184M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas LUCD's P/E ratio is -2.61. In terms of profitability, HYPR's ROE is -1.00%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, HYPR is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
HYPR vs MDGS Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas MDGS's P/E ratio is -0.27. In terms of profitability, HYPR's ROE is -1.00%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, HYPR is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check MDGS's competition here
Quantum-Si incorporated (NASDAQ: QSI)
HYPR vs QSI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, QSI has a market cap of 165.2M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while QSI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas QSI's P/E ratio is -1.82. In terms of profitability, HYPR's ROE is -1.00%, compared to QSI's ROE of -0.47%. Regarding short-term risk, HYPR is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check QSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
HYPR vs QIPT Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas QIPT's P/E ratio is -15.87. In terms of profitability, HYPR's ROE is -1.00%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, HYPR is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
HYPR vs FOCL Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while FOCL trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas FOCL's P/E ratio is -3.99. In terms of profitability, HYPR's ROE is -1.00%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, HYPR is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check FOCL's competition here
Inogen, Inc. (NASDAQ: INGN)
HYPR vs INGN Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, INGN has a market cap of 151.9M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while INGN trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas INGN's P/E ratio is -6.16. In terms of profitability, HYPR's ROE is -1.00%, compared to INGN's ROE of -0.13%. Regarding short-term risk, HYPR is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
HYPR vs QTRX Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, QTRX has a market cap of 140.8M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while QTRX trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas QTRX's P/E ratio is -1.18. In terms of profitability, HYPR's ROE is -1.00%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, HYPR is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check QTRX's competition here
LENSAR Inc (NASDAQ: LNSR)
HYPR vs LNSR Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, LNSR has a market cap of 106.6M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while LNSR trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas LNSR's P/E ratio is 8.86. In terms of profitability, HYPR's ROE is -1.00%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, HYPR is more volatile compared to LNSR. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check LNSR's competition here
iCAD, Inc. (NASDAQ: ICAD)
HYPR vs ICAD Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas ICAD's P/E ratio is -20.37. In terms of profitability, HYPR's ROE is -1.00%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, HYPR is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for HYPR.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
HYPR vs HJLI Comparison August 2026
Hyperfine, Inc. (NASDAQ: HYPR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HYPR stands at 76M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, HYPR is priced at $0.90 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HYPR currently has a P/E ratio of -2.44, whereas HJLI's P/E ratio is N/A. In terms of profitability, HYPR's ROE is -1.00%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, HYPR is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for HYPR.Check HJLI's competition here